The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of advanced gastric cancer (AGC)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Second People's Hospital of Sichuan
• Treatments: Capecitabine; Oxaliplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Age ≥ 18 years old

• male or female

• Patients with stage IV gastric cancer by pathology or cytology and imaging diagnosis , or after previous surgery or radiotherapy or chemotherapy in patients with stage IV gastric cancer progression , there RECIST criteria evaluable lesions ;

• ECOG performance status score 0-2 ;

• Expected survival time more than three months ;

• Adequate hematologic parameters and liver and kidney function ;

• Bone marrow : absolute neutrophil count (ANC) ≥ 1.5 × 109 / L, platelets ≥ 75 × 109 / L, hemoglobin ≥ 80g / L;

• Liver: bilirubin ≤ 1.5 times the upper limit of normal , ALT AST values ≤ 2.5 times the upper limit of normal ;

• Renal : serum creatinine ≤ ULN ;

• Informed consent of patients or their agents , and signed informed consent.

Exclusion Criteria:

• For patients allergic to capecitabine ;

• Patients with CNS metastases

• Undermine the integrity of the upper gastrointestinal tract , malabsorption syndrome , or unable to take oral medication ;

• Patients with coronary heart disease , angina , myocardial infarction , arrhythmia, cerebral thrombosis, stroke and other serious cardiovascular and cerebrovascular disease ;

• Or in combination with other anti-tumor therapy in patients participating in clinical trials of other interventions ;

• Pregnancy or breast-feeding patients , or fertility without taking adequate contraceptive measures were ;

• The researchers believe that this test is not suitable for those who participate .